AstraZeneca PLC (AZN)
After hours:
| Previous close | 66.07 |
| Open | 64.10 |
| Bid | 64.26 x 2900 |
| Ask | 66.26 x 1300 |
| Day's range | 64.07 - 65.96 |
| 52-week range | 53.63 - 71.70 |
| Volume | |
| Avg. volume | 7,019,755 |
| Market cap | 204.375B |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.36 |
| Earnings date | N/A |
| Forward dividend & yield | 1.44 (2.17%) |
| Ex-dividend date | 24 Feb 2022 |
| 1y target est | 71.80 |
- Zacks
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
Astrazeneca (AZN) closed at $65.95 in the latest trading session, marking a -0.18% move from the prior day.
- Business Wire
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers
WILMINGTON, Del., July 01, 2022--AstraZeneca presented data for IMFINZI® (durvalumab) combinations from the HIMALAYA and TOPAZ-1 Phase III trials at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL 2022) and the European Society for Medical Oncology’s World Congress on Gastrointestinal Cancer (ESMO World GI 2022).
- Financial Times
Oxford BioMedica extends Covid vaccine deal with AstraZeneca
Oxford BioMedica has extended its partnership with AstraZeneca, agreeing a new three-year contract to manufacture Covid-19 vaccines if the UK drugmaker presses on with mass production of the jab. The specialist pharmaceutical manufacturer, which also makes cell and gene therapies, will make its Oxbox facility available on an “as needed” basis to AstraZeneca after 2022. The original contract signed in September 2020 is expected to complete in the last quarter of this year, with Oxford BioMedica recognising roughly £30mn from AstraZeneca this financial year.
